CMS Issues Lowest Part D Premium Since 2013: AHIP Warns Rebate Rule Could Impact This
CMS has announced the average basic Part D premium for 2021 will be $30.50. This presents a slight uptick from [...]
Podcast: Will Patients See Lower Rx Prices, from Trump’s Executive Order?
The latest Patients Rising Podcast features Terry and Bob discussing policies such as co-pay accumulators and rebates, while Katy Talento [...]
The Cost Argument: Requiring Masks for COVID-19
Patients Rising, a national nonprofit organization dedicated to providing support and education to people with chronic and life-threatening illnesses, summarizes [...]
New Value & Outcomes Spotlight Editors Take the Helm
New Editors-in-Chief were recently appointed for Value & Outcomes Spotlight. Zeba M. Khan, RPh, PhD and Laura T. Pizzi, PharmD, [...]
ISPOR Europe 2020 Is Now Virtual | 14-18 November
Virtual ISPOR Europe 2020, “Improving Health: Establishing Incentives and Sharing Value,” will now be held as a completely virtual conference. [...]
ISPOR’s CSO Dr. Lucinda Orsini shares views on use of RWE by regulators and HTAs
In this interview with Lucinda Orsini, D.P.M., M.P.H., the Associate Chief Science Officer for the Professional Society for Health Economics [...]
Aetion analyzes RWE impact in 4 recent FDA decisions in infectious disease
Senior Directors from Aetion (Purpura and Harvey) analyzed four approvals for products intended to treat or prevent infectious diseases from [...]
A Digital Bridge To Real-Time COVID-19 Data
Several years ago, the Digital Bridge collaborative was formed, consisting of representatives from three key stakeholder communities: public health, the health care [...]
AMCP Introduces AMCP Collaborate online community to engage in discussions of managed care
AMCP, the organization for managed care pharmacists, today introduced AMCP Collaborate, an online community designed to give members a new platform to engage [...]
5 Questions for the New Chair of NICE Sharmila Nebhrajani
S. Nebharajani assumed the role of chair of NICE in May 2020, most recently serving as CEO of Wilton Park, [...]
Former FDA Commish Califf: Weighing the Benefits & Risks of the Growing Number of Observational Treatment Assessments
In a recently published JAMA Viewpoint, former FDA Commissioner Robert Califf and colleagues mused about a growing concern about inferring [...]
Trump v. Pharma: a “Kinda Sorta” War
Politico summarizes Trump's "kinda sorta" war with pharma, kicked off last week with presidential tweets about "nasty" drug ads that [...]
Unsupported Price Hikes: Drug manufacturers will be penalized in NASHP’s new model bill
The National Academy for State Health Policy’s (NASHP) newly introduced model law, an Act to Protect Consumers from Unsupported Price Increases [...]
Medicare turns 55, and now’s the time to look at Part D – did it work?
On July 30, 1965, President Lyndon B. Johnson signed into law legislation that established the Medicare and Medicaid programs. The [...]
New Data Released: Higher cost-sharing for brand medicines experienced by commercially insured patients
Health plans are increasingly using deductibles and coinsurance to shift more of the cost of care to chronically ill patients [...]
Payers probably won’t pass COVID savings onto members, despite pandemic-driven boon
Payers were prepared for skyrocketing medical costs due to COVID, but the opposite happened: people consumed less healthcare, on average. [...]
Not interested: Pharma execs refuse White House meeting over drug pricing executive orders
Trump's recent executive orders linking drug prices in Medicare to lower prices abroad caused a significant rift with the pharma [...]
High-Value Care Every Time: Recommendations From The National Quality Task Force
To address the high-cost, low-value healthcare dilemma in the United States, the National Quality Forum (NQF) launched the National Quality [...]
Cytel Scientists Call for a “Statistician-First Workflow” to Optimize Drug Development
Adaptive trial designs within oncology are described by Cytel scientists, and address data, statistical, and commercial and scientific value of [...]
Incorporating Value-based Care Into Oncology
Value-based care within insurance design utilizes evidence-based medicine to distinguish high-value and low-value diagnostics and treatments. The goals of value-based [...]
Viewpoint in JAMA: Integrating Personalized Medicine with Population Health Management: The Path Forward
In this viewpoint article published in the Journal of the American Medical Association, the authors posit that genome-wide DNA sequencing [...]
A Military-Civilian Perspective on Real-World Evidence to Support Regulatory Decision Making
This article summarizes how the US Military Health System (MHS) used real-world data (RWD) during the Iraq and Afghanistan Wars [...]
New Report: Provider Perceptions of Value-Based Care
Provider Perceptions of Value-Based Care aimed to understand provider views on value-based care and their partnership with private and public [...]
BresMed White Paper: 8 Common Challenges with Rare Disease Drug Value and How to Address Them
BresMed, and international HEOR consultancy, developed a white paper exploring eight key challenges that manufacturers face when demonstrating the value [...]
Dread Expressed by Public Health Experts on Hurried FDA Signoff on COVID-19 Vaccine
Eighty-nine sites are enrolling patients in the landmark Phase 3 trial for Moderna Therapeutics vaccine kicked off on Monday, July [...]